Citigroup’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-194,090
| Closed | -$1.13M | – | 6035 |
|
|
2022
Q4 | $1.13M | Buy |
194,090
+73,373
| +61% | +$386K | ﹤0.01% | 2502 |
|
|
2022
Q3 | $809K | Buy |
+120,717
| New | +$732K | ﹤0.01% | 2873 |
|
|
2021
Q4 | – | Sell |
-1,669
| Closed | -$5K | – | 6177 |
|
|
2021
Q3 | $5K | Sell |
1,669
-281
| -14% | -$985 | ﹤0.01% | 5599 |
|
|
2021
Q2 | $8K | Sell |
1,950
-622
| -24% | -$2.63K | ﹤0.01% | 5751 |
|
|
2021
Q1 | $13K | Sell |
2,572
-3,967
| -61% | -$32.1K | ﹤0.01% | 5511 |
|
|
2020
Q4 | $83K | Buy |
6,539
+5,165
| +376% | +$58.9K | ﹤0.01% | 5691 |
|
|
2020
Q3 | $13K | Sell |
1,374
-44,936
| -97% | -$443K | ﹤0.01% | 6483 |
|
|
2020
Q2 | $461K | Buy |
46,310
+37,886
| +450% | +$363K | ﹤0.01% | 4338 |
|
|
2020
Q1 | $74K | Buy |
8,424
+3,289
| +64% | +$32.4K | ﹤0.01% | 5625 |
|
|
2019
Q4 | $47K | Buy |
5,135
+2,020
| +65% | +$14.3K | ﹤0.01% | 6364 |
|
|
2019
Q3 | $18K | Sell |
3,115
-4,439
| -59% | -$47.1K | ﹤0.01% | 6808 |
|
|
2019
Q2 | $91K | Buy |
7,554
+463
| +7% | +$4.98K | ﹤0.01% | 5962 |
|
|
2019
Q1 | $85K | Buy |
7,091
+1,739
| +32% | +$25.6K | ﹤0.01% | 5907 |
|
|
2018
Q4 | $67K | Buy |
5,352
+136
| +3% | +$1.88K | ﹤0.01% | 5995 |
|
|
2018
Q3 | $77K | Buy |
5,216
+1,336
| +34% | +$21K | ﹤0.01% | 6150 |
|
|
2018
Q2 | $65K | Buy |
3,880
+99
| +3% | +$1.92K | ﹤0.01% | 6088 |
|
|
2018
Q1 | $87K | Sell |
3,781
-738
| -16% | -$16.4K | ﹤0.01% | 5734 |
|
|
2017
Q4 | $117K | Buy |
4,519
+696
| +18% | +$14K | ﹤0.01% | 5505 |
|
|
2017
Q3 | $56K | Sell |
3,823
-64
| -2% | -$929 | ﹤0.01% | 5938 |
|
|
2017
Q2 | $54K | Buy |
3,887
+2,993
| +335% | +$44.1K | ﹤0.01% | 5735 |
|
|
2017
Q1 | $15K | Buy |
894
+55
| +7% | +$660 | ﹤0.01% | 6402 |
|
|
2016
Q4 | $9K | Hold |
839
| – | – | ﹤0.01% | 6789 |
|
|
2016
Q3 | $8K | Sell |
839
-6,089
| -88% | -$66.5K | ﹤0.01% | 6638 |
|
|
2016
Q2 | $78K | Sell |
6,928
-8,607
| -55% | -$110K | ﹤0.01% | 5274 |
|
|
2016
Q1 | $212K | Buy |
15,535
+6,713
| +76% | +$96.6K | ﹤0.01% | 5032 |
|
|
2015
Q4 | $167K | Buy |
8,822
+6,728
| +321% | +$146K | ﹤0.01% | 4913 |
|
|
2015
Q3 | $39K | Sell |
2,094
-801
| -28% | -$13.6K | ﹤0.01% | 5603 |
|
|
2015
Q2 | $43K | Buy |
2,895
+516
| +22% | +$7.86K | ﹤0.01% | 5635 |
|
|
2015
Q1 | $36K | Sell |
2,379
-1,579
| -40% | -$22K | ﹤0.01% | 5739 |
|
|
2014
Q4 | $53K | Buy |
3,958
+3,907
| +7,661% | +$50.5K | ﹤0.01% | 5656 |
|
|
2014
Q3 | $1K | Sell |
51
-57,566
| -100% | -$558K | ﹤0.01% | 6956 |
|
|
2014
Q2 | $582K | Buy |
57,617
+55,213
| +2,297% | +$533K | ﹤0.01% | 3356 |
|
|
2014
Q1 | $32K | Buy |
+2,404
| New | +$33.9K | ﹤0.01% | 5774 |
|
Citigroup's CNCE Position: Q1 2023 in Review
Citigroup sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 194,090 shares — an estimated $1.13M sold.
Citigroup first reported a position in CNCE in Q1 2014 and held it in 33 quarters. The position peaked at $1.13M in Q4 2022. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- Citigroup reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Citigroup sold 194,090 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $1.13M.
- Citigroup first reported a position in Concert Pharmaceuticals, Inc. in Q1 2014 and held it in 33 quarters.
- Citigroup's Concert Pharmaceuticals, Inc. position peaked at $1.13M in Q4 2022.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on Citigroup's 13F filing for Q1 2023, filed 11 May 2023.